Influvac Tetra

B/Phuket/3073/2013-like virus and B/Austria/1359417/202 virus, the active ingredient in Influvac Tetra, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It stimulates the immune system to produce protective antibodies against these influenza B strains, helping to prevent influenza infection in eligible individuals such as children and adults.

GNH USA supplies Influvac Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance, and reliable cold‑chain logistics for vaccine distribution.

Influvac Tetra is a quadrivalent influenza vaccine used to prevent seasonal influenza caused by specific B virus strains. Seasonal influenza (B/Phuket/3073/2013-like strain): Provides protective immunity to reduce the risk of infection with this circulating B virus. Seasonal influenza (B/Austria/1359417/202 strain): Induces antibody response that lowers the incidence of illness caused by this B virus. Children aged 6 months and older: Helps decrease laboratory‑confirmed influenza cases in pediatric populations.

Common and serious adverse reactions may occur after administration of Influvac Tetra.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness: localized erythema around the injection area. - Swelling: temporary edema at the site of administration. - Fever: low‑grade temperature rise within 24‑48 hours.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder that may develop after vaccination.

Precautions should be observed before administering Influvac Tetra. Allergy assessment: verify no previous severe reaction to influenza vaccines or any component. Pregnancy and lactation: consult healthcare provider; vaccine may be administered if benefits outweigh potential risks. Immunocompromised patients: vaccine may be less immunogenic; timing should be coordinated with treating physician. Age eligibility: approved for individuals aged 6 months and older. Concurrent medications: no specific contraindication, but inform provider of immunoglobulins or steroids. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be considered when planning vaccination. Major Interactions (Avoid): - Live attenuated vaccines: avoid simultaneous administration; separate by at least 4 weeks. - Immunoglobulin therapy: avoid within 2 weeks before or after vaccination. Moderate Interactions (Monitor Closely): - Antipyretic medications (acetaminophen, ibuprofen): prophylactic use may diminish antibody response; monitor. - Immunosuppressive drugs (e.g., corticosteroids, chemotherapy): may reduce vaccine efficacy; monitor. - Antihistamines: may mask mild allergic reactions; monitor.